Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Thus, the amount of material left is 2−1 = 1/2 raised to the (whole or fractional) number of half-lives that have passed. Thus, after 3 half-lives there will be 1/23 = 1/8 of the original material left. Therefore, the mean lifetime
== Structures == CLE peptides are coded by the CLE genes. These peptides vary in structure, with each peptide structure performing a different job within the plant. The minimal length of functioning CLE peptides has been found to be 12 amino acids with several critical residues. There are two different peptide structures that are found within the plant and they are A-type and B-type. When A-type hormones are secreted the plant slows down the rate of root growth whereas the secretion of B-type peptides effects the vascular growth of the plant. The secretion of A-type peptides speeds up the vascular development of the plant that is mediated by the B-type peptides. This suggests that these two types of peptides work together to regulate the growth of the plant. The specific peptides are: A-type peptides
== Terminology == Scottish law professor James Lorimer is credited with coining the term "international organization" in an 1871 article in the Revue de Droit International et de Legislation Compare. Lorimer used the term frequently in his 2-volume Institutes of the Law of Nations (1883, 1884). Other early uses of the term were by law professor Walther Schucking in works published in 1907, 1908 and 1909, and by political science professor Paul S. Reinsch in 1911. In 1935, Pitman B. Potter defined international organization as "an association or union of nations established or recognized by them for the purpose of realizing a common end". He distinguished between bilateral and multilateral organizations on one end and customary or conventional organizations on the other end. In his 1922 book An Introduction to the Study of International Organization, Potter argued that international organization was distinct from "international intercourse" (all relations between states), "international law" (which lacks enforcement) and world government. International Organizations are sometimes referred to as intergovernmental organizations (IGOs), to clarify the distinction from international non-governmental organizations (INGOs), which are non-governmental organizations (NGOs) that operate internationally. These include international nonprofit organizations such as the World Organization of the Scout Movement, International Committee of the Red Cross (ICRC), and Médecins Sans Frontières, as well as lobby groups that represent the interests of multinational corporations.
Tanzi, RE; Petrukhin, K; Chernov, I; Pellequer, JL; Wasco, W; Ross, B; Romano, DM; Brzustowicz, LM; Devoto, M; Peppercorn, J; Bush, AI; Sternlieb, I; Pirastu, M; Gusella, JF; Evgrafov, O; Penchaszadeh, GK; Honig, B; Edelman, IS; Soares, MB; Scheinberg, IH; Gilliam, TC (1993). "Identification of the Wilson's disease gene: A copper transporting ATPase with homology to the Menke's disease gene". Nature Genetics. 5 (4): 344–350. Bibcode:1993NaGen...5..344T. doi:10.1038/ng1293-344. PMID 8298641. S2CID 610188. Levy-Lahad, E; Wasco, W; Poorkaj, P; Romano, DM; Oshima Jm, Pettingell WH; Yu, C; Jondro, PD; Schmidt, SD; Wang, K; Crowley, AC; Fu, Y-H; Guenette, SY; Galas, D; Nemens, E; Wijsman, EM; Bird, TD; Schellenberg, GD; Tanzi, RE (1995). "Candidate gene for the chromosome 1 familial Alzheimer's disease locus". Science. 269 (5226): 973–977. Bibcode:1995Sci...269..973L. doi:10.1126/science.7638622. PMID 7638622. S2CID 27296868. Bertram, L; Blacker, D; Mullin, K; Keeney, D; Jones, J; Basu, S; Yhu, S; McInnis, M; Go, R; Vekrellis, K; Selkoe, D; Saunders, A; Tanzi, RE (2000). "Evidence for genetic linkage of Alzheimer's disease to chromosome 10q". Science. 290 (5500): 2302–2303. Bibcode:2000Sci...290.2302B. doi:10.1126/science.290.5500.2302. PMID 11125142. Bertram, L; Hiltunen, M; Parkinson, M; Ingelsson, M; Lange, C; Ramasamy, K; Mullin, K; Menon, R; Sampson, AJ; Hsiao, MY; Elliott, KJ; Moscarillo, T; Hyman, BT; Wagner, SL; Becker, KD; Blacker, D; Tanzi, RE (2005). "Family-based association between Alzheimer's disease and variants in UBQLN1". N. Engl. J. Med. 352 (9): 884–894.
Journal of Military History. 65 (3): 617–640. doi:10.2307/2677528. JSTOR 2677528. S2CID 159945703. McEvedy, Colin; Jones, Richard (1978). Atlas of World Population History. Facts on File. ISBN 978-0-87196-402-1. McLynn, Frank (1998). Napoleon: A Biography. Pimlico. ISBN 978-0-7126-6247-5. Munch-Petersen, Thomas (2007). Defying Napoleon: How Britain Bombarded Copenhagen and Seized the Danish Fleet in 1807. Sutton. ISBN 978-0-7509-4280-5. Palmer, Robert Roswell (1941). Twelve who Ruled: The Committee of Public Safety, During the Terror. Princeton University Press. Palmer, Alan (1974). Alexander I: Tsar of War and Peace. Weidenfeld & Nicolson. ISBN 978-0-297-76700-8. Palmer, R. R.; Colton, Joel; Kramer, Lloyd (2013). A History of the Modern World: 11th Edition. McGraw-Hill Higher Education. ISBN 978-0-07-759962-1. Payne, Stanley G. (1973). A History of Spain and Portugal: Eighteenth Century to Franco. Vol. 2. Madison: University of Wisconsin Press. ISBN 978-0299062705. Retrieved 2 May 2021. Philo, Tom (2010), Military and Civilian War Related Deaths Through the Ages, archived from the original on 20 April 2010 Rapport, Mike (2013). The Napoleonic Wars: A Very Short Introduction. OUP Oxford. ISBN 978-0-19-164251-7. Riehn, Richard K. (1990). 1812: Napoleon's Russian Campaign. McGraw-Hill. ISBN 978-0-07-052731-7. Riehn, Richard K. (1991), 1812: Napoleon's Russian Campaign (Paperback ed.), New York: Wiley, ISBN 978-0-471-54302-2 Riley, J. P. (2013). Napoleon and the World War of 1813: Lessons in Coalition Warfighting. Routledge. ISBN 978-1-136-32135-1. Roberts, Andrew (2014).
Sources: en.wikipedia.org
== Cellular cardiomyoplasty == Cellular cardiomyoplasty is a method which augments myocardial function and cardiac output by directly growing new muscle cells in the damaged myocardium (heart muscle). Tissue engineering, which is now being categorized as a form of regenerative medicine, can be defined as biomedical engineering to reconstruct, repair, and improve biological tissues. Research efforts in tissue engineering have been ongoing and it is emerging as one of the key areas of medical research. Furthermore, there are vast developments in tissue engineering, which involve leveraging of technologies from biomaterials, molecular medicine, biochemistry, nanotechnology, genetic and biomedical engineering for regeneration and cell expansion targets to restructure and/or repair human organs. Injection of cardiomyogenic and/or angiogenic stem cells have been proposed as alternatives to existing treatments. For cardiovascular application, skeletal myoblasts are of great interest as they can be easily isolated and are associated with high proliferation rate. These cells have also been demonstrated to be hypoxia-resistant. Bone marrow contains different cell populations, which exhibit excellent plasticity toward cardiogenic and endothelial cells. These cell populations are endothelial progenitor cells, hematopoietic stem cells and mesenchymal stem cells. Adipose tissue host progenitor cells with reported interesting cardiomyogenic and vasculogenic potential in the sense that they improve heart functions and reduce infarction size in rodent animal models.
This process through which perceived inferiority can be exercised physically can be looked back on through a foundational perspective of the "Nigrescence Theory". This theory explains the distinction of one's own socialized identity through various stages, and the pigmentation of the skin that someone is born with that is associated with the socialization process within a culture. More specifically, out of the four stages associated with this theory, the first one, named the "pre-encounter" stage, highlights the underlying concept one not associating themselves with their own culture or values due partly to the misinformation one has been taught to believe and therefore seeks validation and worthiness from those who have misinformed that person.
Baldwin's famous speech led many to believe the only way to prevent the bombing of British cities was to make a strategic bomber force so large it could, as Baldwin put it, "kill more women and children more quickly than the enemy." Even the highest levels of the RAF came to agree with this policy, publicly stating that their tests suggested that "'The best form of defence is attack' may be all-too-familiar platitudes, but they illustrate the only sound method of defending this country from air invasion. It is attack that counts." As it became clear the Germans were rapidly rearming the Luftwaffe, the fear grew RAF could not meet the objective of winning such a tit-for-tat exchange and many suggested they invest in a massive bomber building exercise. Others felt advances in fighters meant the bomber was increasingly vulnerable and suggested at least exploring a defensive approach. Among the latter group was Lindemann, test pilot and scientist, who noted in The Times in August 1934 that "To adopt a defeatist attitude in the face of such a threat is inexcusable until it has definitely been shown that all the resources of science and invention have been exhausted."
Germany was particularly important in the early modernist movement: it is the home of Werkbund initiated by Hermann Muthesius (New Objectivity), and of the Bauhaus movement founded by Walter Gropius. Ludwig Mies van der Rohe became one of the world's most renowned architects in the second half of the 20th century; he conceived of the glass façade skyscraper. Renowned contemporary German architects and offices include Pritzker Prize winners Gottfried Böhm and Frei Otto.
Sources: en.wikipedia.org
=== Alternative modulations === The DASH7 Alliance policy forbids the addition of proprietary or licensable modulation techniques in the official DASH7 Alliance Protocol. However, the layered structure of the protocol allows simple integration of alternative modulations, such as LoRa, under the network layer (D7ANL).
Tamales – although largely associated with Mexico, and its indigenous Mesoamerican origin, records from the Iroquoian people show that they too made such a dish. Taxation – the Inca had a sophisticated taxation system, the mit'a, using quipus (knotted strings) as recording devices. Quipus were transported through the Inca road network messengers (chaskis) and administered by the quipu authorities (quipucamayoc). Tipi – a cone-shaped, portable dwelling popularized by Plains Indians (Native Americans and First Nations) of the Great Plains and the Canadian Prairies. Tipis were warm, durable, comfortable, and could be easily disassembled and packed. A settlement could be ready to move in about one hour. Tlingit armor – Tlingit armor was worn by coastal Indigenous nations in Alaska and British Columbia. Tlingit warriors wore battle helmets depicting either crest animals or ancestors, along with wooden visors, thick leather tunics, and body armor covered with wooden slats or coins. This battle attire combines technology, ingenuity, and symbolic power and protection. Tobacco – tobacco was used in the Americas for many centuries prior to the arrival of white Europeans. Consumed in high doses, tobacco can become highly hallucinogenic and was accordingly used by many indigenous peoples in the Americas to inspire dreams and dreamtime. Tobacco was also often consumed as a medicine amongst some tribes, although this was strictly practiced by experienced shamans and medicine men.
Related peer-reviewed clinical research documented the successful short-term implantation of a remotely programmable insulin delivery system in humans, reflecting the collaboration between Sandia engineers and University of New Mexico clinicians. These efforts represent an important component of the early development of implantable insulin delivery systems, highlighting the role of U.S. national laboratories in advancing biomedical device technology alongside academic and commercial research.
Some Prefer Nettles (蓼喰う虫, Tade kū mushi; Historical orthography: 蓼喰ふ蟲) is a 1929 novel by Jun'ichirō Tanizaki. It was first published in 1928–9 as a newspaper serial. The novel is often regarded as the most autobiographical of Tanizaki's works and one of his finest novels. The Japanese title of the novel is literally water pepper-eating bugs, and is the first half of the Japanese saying tade kuu mushi mo sukizuki (蓼食う虫も好き好き), or "Water pepper-eating bugs eat it willingly", equivalent to the English "To each his own." The translation as Some Prefer Nettles was chosen by Edward Seidensticker. He considered it one of his most noted translations, and it has been included as a translation of the original saying in the authoritative Kenkyūsha's New Japanese-English Dictionary.
In 1973, Cold Storage's Pasaraya Malaysia, a joint venture of Cold Storage's subsidiary Supermarkets Malaysia and "Malaysian interests" was responsible for the construction of Jaya Supermarket in Petaling Jaya, set to be completed in April 1974. In 1985, Cold Storage Malaysia opened its first Majik Market store in Bangsar Baru, Kuala Lumpur, It operated under a franchise from Mumford Inc of Atlanta, USA, which complements its existing Jaya Supermarket chain but differ in concept and management. Due to competition from 7-Eleven, whose Malaysian franchise was then operated by the Antah Holdings group, Cold Storage Malaysia phased out Majik Market as part of its streamlining process. Cold Storage Malaysia, along with Peremba, Gaya Timur and Jusco were responsible for the initial version of Jaya Jusco "superstores" in 1985, with three stores in Dayabumi, Taman Tun Dr Ismail and Subang Jaya. In 1987, Cold Storage Malaysia, which had been through a difficult financial phase in the previous three years, had a change in management with some senior executives leaving. In 1992, DFI Retail Group purchased the company, although no major changes were made to the Cold Storage brand. Cold Storage started the Fresh Food Distribution Centre in Singapore in 1999, a composite multi-temperature warehousing for fresh and frozen food distribution. In 2023, DFI Retail Group divested its Malaysian food retailing business (including Cold Storage brand in that country) to Macrovalue Sdn Bhd.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.